Show simple item record

dc.contributor.advisorIslam, Farzana
dc.contributor.authorKarim, Azrin
dc.date.accessioned2024-10-22T06:34:58Z
dc.date.available2024-10-22T06:34:58Z
dc.date.copyright©2024
dc.date.issued2024-01
dc.identifier.otherID 20146077
dc.identifier.urihttp://hdl.handle.net/10361/24372
dc.descriptionThis project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.en_US
dc.descriptionCataloged from PDF version of project report.
dc.descriptionIncludes bibliographical references (pages 43-46).
dc.description.abstractThis review delves into the intricate landscape of Poly ADP-ribose polymerase (PARP) inhibitors, specifically focusing on two notable contenders in cancer therapy – Talazoparib and Olaparib. By targeting the DNA Damage Repair (DDR) signaling system crucial for cancer growth, these inhibitors disrupt essential mechanisms like homologous recombination, base excision repair, and mismatch repair. Talazoparib, a PARP inhibitor, has demonstrated its potential as a breakthrough in metastatic breast cancer with BRCA1/2 mutations, surpassing traditional chemotherapy in efficacy. Through PARP trapping and catalytic inhibition, Talazoparib disrupts repair processes, earning approval for BRCA-mutated breast cancer and homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer.Similarly, Olaparib, another PARP inhibitor, is approved for treating pancreatic, ovarian, breast, and prostate cancers. Its impact on synthetic lethality in cancer cells with BRCA mutations is evident, blocking PARP-mediated repair of single-strand breaks. Clinical trials affirm Olaparib's manageable safety profile and efficacy in treating HER2-negative metastatic breast cancer, prostate cancer, and ovarian cancer. The study concludes that Olaparib and Talazoparib stand as effective therapeutic options across various cancer types and genetic abnormalities. It aims to enlighten medical professionals about the potential of precision medicine in advancing cancer therapy, emphasizing the need for personalized approaches in clinical practice.en_US
dc.description.statementofresponsibilityAzrin Karim
dc.format.extent47 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectPARP inhibitorsen_US
dc.subjectOlapariben_US
dc.subjectTalazopariben_US
dc.subjectDNA damage repairen_US
dc.subjectDDR signaling pathwayen_US
dc.subjectHomologous recombination repairen_US
dc.subjectProstate canceren_US
dc.subjectOvarian canceren_US
dc.subjectMetastatic breast canceren_US
dc.subjectBRCA mutationsen_US
dc.subject.lcshCancer--Treatment--Genetic aspects.
dc.subject.lcshDNA repair.
dc.subject.lcshNAD-ADP-ribosyltransferase--Inhibitors--Therapeutic use.
dc.subject.lcshAntineoplastic agents.
dc.titleA review on newly approved PARP inhibitors: Talazoparib and Olapariben_US
dc.typeProject reporten_US
dc.contributor.departmentSchool of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record